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Abstract
The lack of consensual measures to monitor core change in Autism Spectrum Disorder (ASD) or response to interventions 
leads to difficulty to prove intervention efficacy on ASD core symptoms. There are no universally accepted outcome measures 
developed for measuring changes in core symptoms. However, the CARS (Childhood Autism Rating Scale) is one of the 
outcomes recommended in the EMA Guideline on the clinical development of medicinal products for the treatment of ASD. 
Unfortunately, there is currently no consensus on the response definition for CARS among individuals with ASD. The aim 
of this elicitation process was to determine an appropriate definition of a response on the CARS2 scale for interventions in 
patients with Autism Spectrum Disorder (ASD). An elicitation process was conducted following the Sheffield Elicitation 
Framework (SHELF). Five experts in the field of ASD and two experts in expert knowledge elicitation participated in an 
1-day elicitation workshop. Experts in ASD were previously trained in the SHELF elicitation process and received a dossier 
of scientific evidence concerning the topic. The response definition was set as the mean clinically relevant improvement 
averaged over all patients, levels of functioning, age groups ***and clinicians. Based on the scientific evidence and expert 
judgment, a normal probability distribution was agreed to represent the state of knowledge of this response with expected 
value 4.03 and standard deviation 0.664. Considering the remaining uncertainty of the estimation and the available litera-
ture, a CARS-2 improvement of 4.5 points has been defined as a threshold to conclude to a response after an intervention. A 
CARS-2 improvement of 4.5 points could be used to evaluate interventions’ meaningfulness in indivudals. This initial finding 
represents an important new benchmark and may aid decision makers in evaluating the efficacy of interventions in ASD.
Keywords Autism Spectrum Disorder · Measure · Change · CARS · Response · Expert knowledge elicitation · SHELF
Introduction
Autism Spectrum Disorder (ASD) is a common neurodevel-
opmental disorder associated with social impairments and 
repetitive behavior and interests [1]. Intervention for ASD 
has been the focus of intensive research over recent years 
[2, 3]. With the increase of ASD prevalence, it has become 
extremely important to develop appropriate biomedical, 
behavioral***** and developmental treatments [4]. Advance 
in this field remains nevertheless complicated, one major 
hindrance being the lack of consensual measures to moni-
tor core change in ASD or response to interventions which 
lead to difficulty to prove intervention efficacy on ASD core 
symptoms [2, 4, 5].
Efficacy claims of an intervention require not only sta-
tistical significance but also clinical meaningfulness. One 
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proposed approach to address this question is a responder 
analysis, in which a continuous primary efficacy measure 
is dichotomized into "responders" and "non-responders." 
Such responder classifications help in interpreting data 
clinically and speak directly to the question of funda-
mental interest in clinical science and practice: “Is this 
therapy benefitting the patient? “. Responder definitions 
are based on a threshold of changes in endpoint scores and 
are defined as a magnitude of change that is considered 
important to the patient.
If experts emphasize the need to develop psychometri-
cally sound outcome measures [5, 6], it is also well reported 
that the proliferation of a scattered variety of instruments 
to assess changes in specific symptoms or abilities prevent 
effective comparisons across intervention studies and the 
development of best practice recommendations [2, 3, 5]. 
That is why the core symptoms of ASD represent obvious 
outcome measurement targets [6] and should, if possible, 
be assessed with one or few tools. It is also important to 
be able to monitor progress in a way that is not only reli-
able and systematic but also practical and time-efficient for 
families, schools**** and other service providers. It needs 
to be accessible in different countries (translated in different 
languages) to allow the use of common assessments across 
locations [5]. It is also important to have a tool that suits 
***for individuals from various age ranges in order to be 
able to conduct reliable follow-up studies (e.g. following a 
cohort of adolescent patients as they reach adulthood)[2].
Very few tools suit all these criteria. The CARS-2 was 
chosen in our study as it is a well-established, widely used 
measure with good psychometric properties, recommended 
by the European Medicines Agency for the development of 
medicinal products for ASD [3, 7–9]. Designed to inform 
autism diagnosis with the use of cut-off scores, it also allows 
to quantify the severity of the disorder, which makes it use-
ful also for outcome evaluation [8, 10]. It contains 15 items 
scored from 1 (no symptom) to 4 (severe symptom) in 0.5 
intervals. Two versions are available: the standard version 
(CARS-ST) and the “high functioning” version (CARS-HF), 
adapted for verbally fluent individuals older than 6 with an 
intellectual quotient greater than 80. For the CARS-ST, a 
total score of 15–29.5 is in favor of the absence of ASD 
diagnosis; a score of 30–36.5 reflects mild to moderate 
autism; a score of 37–60 reflects moderate to severe autism. 
For the CARS-HF, cut-off scores are defined as 15–27.5 for 
the absence of ASD, 28–33.5 for mild to moderate ASD and 
34–60 for moderate to severe ASD. The tool has been trans-
lated into multiple languages and psychometrics properties 
have been evaluated in a broad age range (from early child-
hood to mid-adulthood), allowing for its use for individuals 
aged 2 years old and up [8].
Despite its widespread use, little is known about the clini-
cal relevance of the CARS-2 total score and no consensus 
exists on the minimal change in CARS-2 total score which 
should reflect an individual clinically significant improve-
ment. Most of the time clinicians must rely on subjective 
experience with individual patients and populations to inter-
pret CARS-2 scores and the clinical significance of various 
degrees of change. In research setting, guidelines for the 
development of pharmacological treatment recommends 
to complete primary analyses by responder analyses using 
pre-specified criteria for response. As there is currently no 
consensus on the response definition for CARS among indi-
viduals with ASD, an elicitation workshop was organized 
to obtain a balanced scientific assessment of the response 
definition for CARS, based on the evidence.
Opinion-seeking methods, such as expert knowledge elic-
itation, allow the consideration of both clinically important 
and realistic difference [11]. Expert Knowledge Elicitation 
is the formulation of the expert’s knowledge in the form of 
a probability distribution. Elicitation is typically a dialogue 
between experts and a facilitator. The facilitator is knowl-
edgeable in probability and statistics and in how to conduct 
the dialogue in such a way as to elicit the expert’s knowl-
edge as faithfully and with as less influence as possible [12]. 
The experts are selected based on their knowledge about the 
quantity to be determined. Elicitation involves subjective 
judgment, and it is, therefore, important for the exercise to 
be conducted according to a rigorous, well-designed proto-
col, in order to obtain scientifically valid judgments [17].
In order to evaluate an appropriate definition of a 
response on the CARS2 scale for interventions in patients 
with Autism Spectrum Disorder (ASD), an expert knowl-
edge elicitation process was conducted using the Sheffield 
Elicitation Framework (SHELF), one of the leading proto-
cols in the field [13].
Method
Expert selection/participants
Experts were selected to participate to the elicitation task, 
according to the following criteria: (a) experts were all 
familiar with ASD as a result of extensive clinical and/or 
research practice; (b) they all had a background in conduct-
ing research in the field of ASD; (c) experts should col-
lectively cover knowledge regarding various age groups 
and intellectual functioning in ASD individuals; (d) experts 
should be familiar with CARS-2 scale for clinical or research 
use.
In addition to these mandatory criteria, it was considered 
that having an international board (4 different countries) and 
experts with different backgrounds would be of interest to 
cover all perspectives and insights. The experts did not know 
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each other before the process and were selected mainly upon 
their publications or established clinical practice.
The expert panel (listed at the end of this article) included 
two children and adolescent psychiatrists, two doctors in 
psychology, and one Special Educator and Rehabilitator, 
all of whom were involved in academic research and/or 
were clinically active. No unrepresented areas of expertise 
were identified. The experts thought that, collectively, their 
expertise and experience covered a suitable range of patient 
groups. No expert had a personal or financial interest regard-
ing the elicitation outcome. A summary of the experts’ qual-
ification can be found in Supplementary Material (S1).
Two expert knowledge elicitation facilitators (J.O., T.O.) 
were present to animate the workshop, one to facilitate the 
elicitation process and one to record key details of the elici-
tation session and run the software to fit probability distribu-
tions to the values elicited from the experts.
Literature review/evidence dossier
An evidence dossier was circulated prior to the elicitation 
workshop (Supplementary Material, S2). This dossier pro-
vided summaries of published evidence on CARS-2 score 
changes that were interpreted as being clinically relevant 
in clinical trials [9, 14–17]. Such evidence was scarce and 
very few studies were published at the time of this elicitation 
procedure. Our result will be discussed in regard of these 
studies in the discussion part.
The experts also completed a training course to review 
the CARS-2 rating rules upon the CARS manual description 
for both versions of the scale (standard and high function-
ing). Quotation of two clinical cases was also required to 
evaluate inter-judge fidelity among the experts. This also 
served to ensure that the experts had a common understand-




Sheffield Elicitation Framework (SHELF) was used 
to evaluate the definition of a response (also called mean 
minimum clinically relevant change during the elicitation 
process) in CARS2 score (Fig. 1). SHELF is a package of 
documents, templates*** and software to carry out elicita-
tion of probability distributions for uncertain quantities from 
a group of experts. The SHELF templates serve the dual role 
of determining a protocol to minimize cognitive biases and 
Fig. 1  Main steps in SHELF elicitation process
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documenting the elicitation exercise, for a complete review 
see [18].
• Elicitation training
All experts took an online elicitation training course prior 
to the workshop, to familiarize themselves with the kinds of 
judgments that they would be required to make in an elicita-
tion workshop and with how to make those judgments.
At the start of the workshop, the experts completed a 
training example on a subject not related to the subject of 
interest. This served to refresh their online training and to 
introduce them to the procedure for sharing, discussing**** 
and resolving their individual judgments.
• Definition of the quantity of interest (QOI)
The quantity to determine was the minimum clinically 
relevant change in CARS2 score. In accordance with the 
SHELF procedure, the definition of the Quantity of Inter-
est is important. It must be clear to all experts, unambigu-
ous and such that it has a unique (but unknown) value. The 
starting point for this exercise was that a response should 
be the minimum change in CARS2 score that would repre-
sent a clinically relevant benefit a subject with ASD. It was 
noted, however, that the minimal improvement that would be 
regarded as clinically relevant will vary from one patient to 
another, depending on the nature of the patient’s condition, 
their age and the CARS2 items in which the improvement 
arose. Also, a difference that is judged clinically meaningful 
by one clinician might not be by another. Because of this 
variation between patients and clinicians/investigators the 
quantity of interest was defined as a mean, averaged over 
patients, levels of functioning, age groups and clinicians.
The definition of this*** quantity was discussed by the 
experts prior to the elicitation process to assess whether to 
define the quantity of interest as an absolute change, or as a 
relative change. Regarding a scale not including a zero rating 
for the absence of symptoms and a relatively narrow range 
for scoring (from 1 to 4), giving a too heavy relative weight 
to absent symptoms compared to present significant ones, 
it was agreed that absolute changes were easier to interpret. 
Also, the use of a relative change score was deemed prob-
lematic, since it assumes that the change will not be inter-
preted the same way depending on the starting score. For 
example, an improvement of 5 points could lead to a lower 
relative change for participants with high severity of ASD, 
compared to the same improvement in participants with 
milder symptoms. For these two main reasons, all experts 
agreed to consider absolute changes only.
The variable that was elicited was the mean absolute 
numerical change in total CARS2 raw score that would be 
judged by an experienced clinician to represent a minimum 
clinically relevant improvement for a given patient with 
ASD, averaged across all patients, all age groups, all levels 
of functioning and all clinicians.
• Process
According to the SHELF procedure, multiple steps were 
made in the following order: individual elicitation with the 
tertile method, fitting observation, group discussion, group 
elicitation, feedback and discussion, choice of distribution 
and discussion [18].
For the group elicitation, SHELF uses behavioral aggre-
gation where experts are asked to agree on a final prob-
ability distribution representing what a rational impartial 
observer (RIO) might believe after reading the evidence dos-
sier, seeing their experts’ individual judgments and hear-
ing their subsequent discussion [18]. The concept of RIO 
was explained to the experts as a hypothetical person who 
has been standing in the room, listening carefully to all the 
opinions and all the arguments that the experts have given 
in support of their opinions. RIO is supposed to be famil-
iar with the elicitation topic, and so able to understand and 
evaluate those opinions and arguments. It would be unrealis-
tic to imagine that the experts could agree completely about 
likely values of the QOI, even after extensive discussion. 
They would surely leave the workshop with opinions that 
might have been influenced by the discussion but which are 
nevertheless not totally in consensus. Instead, they are asked 
to reach agreement on what a rational impartial observer 
might believe. RIO would not be expected to agree exactly 
with any one expert, but would give some weight to each 
expert’s opinions. By contemplating RIO’s perspective, the 
experts are encouraged also to evaluate and give weight to 
the judgments of their fellow experts. Experience with the 
SHELF protocol, confirmed in the present exercise, suggests 
that this is an effective way for experts to reach a meaningful 
consensus.
Furthermore, the RIO perspective accords well with the 
scientific objectives of an expert knowledge elicitation. The 
objective is generally not to learn what any individual expert 
thinks, nor even to have some average opinion of the selected 
expert group; it is to have a representation of what a rational 
person would believe having studied and debated the rel-
evant evidence.
Statistical analysis
Statistical analysis were conducted live during the elicita-
tion meeting by Jeremy Oakley, using the R package SHELF 
running on R [19, 20]. This process allowed for all experts 
to visualize the QOI distribution on graphs, based on their 
estimations, and to dynamically revise their judgments when 
necessary.




The elicitation workshop took place in Paris, France, on 
March 11th, 2020 and lasted for 1 day. Due to travel restric-
tions during this period due to Covid-19 pandemic, two 
experts and the elicitation’s recorder attended the meeting 
remotely by videoconferencing. For the results section, 
experts will be denoted by letters A, B, C, D, E, and will 
be referred to using feminine pronouns. The facilitator will 
be denoted by Z and referred to using masculine pronouns.
Individual elicitation
Expert were asked to remember that the true value of the 
QOI is unknown, and, therefore, each of them would have 
uncertainty that could be represented as a probability dis-
tribution. Each expert would have her own opinions about 
the mean clinically relevant improvement and, therefore, her 
own probability distribution. They were prompted by the 
facilitator to make a series of judgments to characterize the 
distribution. The lower limit was defined as the minimum 
plausible value, below which the expert should judge if it 
would be very unlikely or implausible to find our QOI and 
vice versa for the upper plausible limit. The expert’s median 
was defined as the value for which the QOI was equally 
likely to be above or below. Finally, the expert’s upper and 
lower tertiles similarly divided the range of plausible values 
into three equally likely parts. These values were written 
by each expert individually, without any group discussion, 
before being communicated to the facilitator. They consti-
tuted individual elicitations, providing grounds for group 
discussion, before moving to the final stage of SHELF where 
experts provide a group consensus on the QOI probability 
function (see below). Expert values are presented in Fig. 2.
Group discussion
The definition of the quantity of interest caused some 
difficulty for the experts. Z prompted some clarification 
from the experts, in order for them to reach a consensus 
on the parameters of the QOI. Several points were made: 
First, the quantity refers to the minimum improvement 
clinicians/investigators would want to see in patients; 
the minimum improvement required for a treatment to be 
considered as benefitting a patient. The expected change, 
hoped-for change or target change due to any particular 
treatment was not deemed relevant to this elicitation exer-
cise. Second, the quantity of interest refers to a minimum 
clinically relevant change. It was made clear that this is 
different from a significant change in the statistical sense 
(e.g. with a p value falling under a preset threshold in a 
clinical trial), such as those already reported in the lit-
erature. Z also pointed out that the QOI is defined as an 
average (mean) clinically relevant improvement, averaged 
over all patients and clinicians. If, for example, the QOI 
were to equal 10 points, that would imply that for about 
50% of patients, clinicians/investigators would require 
an improvement of at least 10 points before judging the 
patients to have had a benefit from treatment.
There is likely to be some variability between measure-
ments taken on the same patient: variability between differ-
ent observers assigning CARS2 scores, and/or variability 
in scores taken at different times on the same patient (even 
with no intervention in between). Small improvements in 
scores consistent with such variability might be dismissed 
as random noise.
The experts noted these points, with experts A and B in 
particular revising their upper limits downwards. Expert D, 
noting that the quantity of interest is defined in terms of the 
minimum required improvement, thought that her upper limit 
of 5 was still appropriate.
There was general agreement that, in a majority of 
patients, an improvement of 5 points would be always judged 
as clinically relevant. In other words, all experts agreed 
on the fact that there is no plausible situation in which an 
increase of 5 points on the scale would not reflect a meaning-
ful improvement. Hence, it was very unlikely that the mean 
minimum required improvement could be greater than 5.
To reach a consensus, the group discussed the results 
presented in the evidence dossier. There was some discus-
sion of the comparison between CGI-I and CARS2 provided 
on page 4 of the evidence dossier (See supplemental mate-
rial S2). Here it was noted that (a) the standard deviation of 
CARS2 scores in the CGI-I responder group was relatively 
large, and (b) that the CARS2 estimates referred to mean 
changes in observed CARS2 scores, not minimum required 
Fig. 2  Individual elicited judgments from each expert on minimum 
clinically important change on CARS-2. The three colored sections 
represent parameter ranges judged to be equally likely by each expert. 
The dashed lines represent the experts’ medians. X represents the 
number of points on the CARS scale
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changes in CARS2 scores. Hence it was judged difficult to 
make inferences from these data.
There was some discussion of Table 3 in the evidence 
dossier (See supplemental material S2) and that 17.4% of 
patients in the placebo group achieved an improvement of 4 
points or more: was this informative for the amount of ‘back-
ground noise’ in CARS scores? One expert noted that, over 
the course of a study involving children and adolescents, 
some patients might improve, even in the placebo group; 
these patients may simply improve as they became older or 
might benefit from a placebo effect (significant improve-
ment through mind–body self-healing processes). Hence an 
improvement of 4 points would not necessarily be dismissed 
as noise.
There was agreement that an improvement of a single 
point would be very unlikely to be judged relevant; the mean 
would need to be greater than 1.
Group elicitation
Then the group of experts was asked to collectively deter-
mine key summaries of the probability distribution of the 
QOI, based on the previous discussion and with as much 
impartiality and rationality as possible (using the rational 
impartial observer framework, see “Methods” section). The 
probability that the QOI was inferior or equal to 3.5 was 
judged to be equal to 0.33. The probability that the QOI was 
superior to 4.75 was judged to be equal to 0.2. The prob-
ability that the QOI was inferior or equal to 4 was judged to 
be equal to 0.45.
The final step is to obtain a probability distribution for the 
QOI to reflect the available knowledge from the perspective 
of the rational impartial observer. The experts’ elicited group 
judgments are the starting point m and this step begins with 
the recorder fitting one or more standard probability distri-
butions to the elicited probabilities. The group judgments 
are difficult for the experts to make, and at best they will be 
approximate. At the fitting stage they will often be varied, 
under the guidance of the facilitator and the recorder, to 
obtain a probability distribution that more accurately repre-
sents the experts’ knowledge and beliefs.
To begin this process, the experts were shown their RIO 
judgments in the form of a histogram and a fitted probability 
distribution. These are depicted in Fig. 3. In discussion with 
the facilitator, the experts agreed that this did not reflect their 
opinions; in particular, it seemed to give too much probabil-
ity to low values of the QOI, particularly values below 1, and 
an unrealistically high probability in the range 4.75–5. It was 
felt that 5 should not be a hard upper limit.
The recorder showed the experts how the histogram and 
fitted distribution would change if the limits and probabili-
ties were varied, and a number of alternative fits were dis-
cussed. Finally, the experts chose:
• to increase the lower plausible limit to2 and the upper 
plausible limit to 6,
• to reduce the first probability to P (X <  = 3.5) = 0.2,
• to reduce the second probability to P (X > 4.75) = 0.15,
• and to increase the third probability to P (X <  = 4) = 0.5.
The final distribution is shown in Fig. 4. In the chosen 
distribution, the fitted 90th percentile was 4.88, and there 
Fig. 3  Histogram and fitted beta distribution depicting the experts’ 
initial group judgments
Fig. 4  The experts’ final judgments and agreed distribution
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was a 7% probability of the QOI exceeding 5. The bulk of 
the probability was in the range 3.5–4.5.
The experts agreed that these features were appropri-
ate and were in accordance with what a rational impartial 
observer would believe, based upon the evidence and the 
points raised during the discussion. The fitted distribution 
was confirmed as the outcome of the elicitation.
Final result: CARS-2 response distribution
A normal distribution with a mean equal to 4.03 and stand-
ard deviation 0.664 was agreed to represent the avail-
able knowledge and evidence regarding the mean absolute 
numerical change in total CARS2 raw score that would be 
judged by an experienced clinician to represent a minimum 
clinically relevant improvement for a given patient with 
ASD, averaged across all patients, all age groups, all levels 
of functioning and all clinicians (Fig. 4).
Discussion
Measuring change in studies pertaining to ASD is a particu-
lar difficulty in the field. CARS-2 is a widely used scale, 
with good psychometric properties, focusing on ASD core 
symptoms, corresponding to European guideline on the clin-
ical development of medicinal products for the treatment 
of ASD [9]. Using an expert elicitation process, the mean 
minimum clinically important change on CARS-2 score was 
determined, to help defining a threshold to identify patients 
that are responders to an intervention. Our results show that 
on average, clinicians would like to see a 4-point improve-
ment, as a minimal change, to conclude to a meaningful 
improvement after an intervention in the context of ASD.
Coherence with other studies
Our result is coherent with available literature on this 
topic (Table 1). In their study on the use of secretin in 
ASD, Chez et al. described that a 6-point improvement in 
ratings is indicative of a « clinically significant» change. 
Their explanation relied on the fact that by virtue of the 
instrument’s design, a change of 6 points in the total score 
leads to a change in severity classifications (e.g. from 
“mild to moderate autistic symptoms” to “minimal to 
no symptoms”) [14]. We proposed a 2-point lower score 
change, with the objective to define a “Minimum” Clini-
cally Important change. Using a reliable change index 
method [21], Coniglio et  al. obtained the exact same 
results as ours [15]. This index method corrects for unreli-
ability of measurement and establishes a standard amount 
of change that is needed for any individual case across 
two repeated measures to be considered either clinically 
improved, unchanged, or deteriorated. Two other stud-
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calculation. One considered a mean difference of 4 points 
in change from baseline in the CARS2 total score [16]. 
The second considered an improvement of at least 20% 
from baseline total score [17].
Lemonnier et al. also described a correlation between 
CARS-2 and CGI-I. No calculation was done to correct the 
mean score at CARS-2 when CGI was reported as “mini-
mally improved” but a graph presented the results with a 
median improvement around 4 points on the CARS cor-
responding to the “minimally improved” category [16].
Choice of a threshold
We could, therefore, recommend that a 4-point CARS2 
improvement could be used as the definition of a response 
outcome in studies of interventions in ASD. In view of the 
remaining uncertainty about the elicited QOI, we might 
also prefer to suggest choosing a 4.5-point improvement, 
because according to the fitted distribution, we can be 
70% sure that the QOI is below 4.5. This threshold is also 
coherent with available literature and is a more cautious 
choice for regulators.
Importance of this result for randomized controlled 
trials
Our study is the first one to propose a threshold for 
a minimum clinically relevant improvement on a scale 
assessing core symptoms of ASD. This threshold could 
be used to assess whether a subject with ASD could be 
considered as a responder or not regarding a treatment.
Concerning our methods, expert elicitation process has 
been recommended mostly when the outcome is particu-
larly complex, which is the case in the context of ASD 
core symptoms [22]. Other methods, such as distribu-
tion-based approaches, rely on statistical characteristics 
to determine important changes in the clinical outcome 
[21, 22]. However, they largely ignore the main objec-
tive, which is to define the clinical importance of a given 
change in outcome scores, separate from their statistical 
significance. On the other hand, anchor-based approaches 
work by relating the outcome of interest to another recog-
nized measure of clinical change: the anchor. However, the 
lack of studies using both CARS and an external criterion 
that could be considered as an anchor prevents from using 
this approach.
Compared to all these approaches, the expert elicitation 
has the advantages to account for the clinical expertise to 
estimate the quantity of interest. It can be used to directly 
elicit a clinically important change in an outcome of interest, 
without the need to use another instrument as a comparator. 
The SHELF protocol enables a clear and transparent way to 
elicit subjective, informed and rational ratings. Wording of 
the initial question was clear and specific; the background 
diversity of the selected experts allowed for a complete cov-
erage on the topic and all the experts agreed with the final 
result.
Limitations
Some difficulties were noted with the definition of the quan-
tity of interest; it was particularly difficult for the experts to 
consider an average minimum clinically relevant improve-
ment across all patients. Ideally, a threshold for a minimum 
clinically relevant improvement might be elicited for differ-
ent ASD subgroups (e.g. high functioning and low function-
ing). Nevertheless, as most of the RCT in ASD considered 
a broad range of participants, a mean minimum clinically 
relevant improvement for all type of ASD participants is 
important to be used as a target change to define a response 
to treatment. As described in the CARS-2 manual, the same 
method of rating is used for the two versions of CARS-2 
(CARS2-ST, CARS2-HF) and the internal structure of the 
two versions and the original version of the CARS are simi-
lar. The experts collectively agreed to define the quantity 
of interest as the mean clinically relevant improvement 
across all patients and all versions [8]. For future studies, 
it would, therefore, be interesting to evaluate each version 
separately, with the use of an anchor-based or distribution-
based method to complete the results the present study.
The SHELF protocol uses a behavioral approach to 
resolve the experts’ judgments into a single distribution. 
The behavioral approach has the difficulty of persuading 
experts with differing opinions to reach “consensus”. Such 
procedure could be impacted by personality issues (e.g. 
introvert experts being less willing to provide their opinion 
compared to extroverts, etc.) or status issues (junior versus 
senior expert). The facilitator’s role is to manage the experts 
and to address possible sources of bias in group interactions. 
The presence of an experienced facilitator in our study was 
designed to avoid unbalanced weighting of arguments in the 
discussion within the experts.
Conclusion
Our results provide a threshold for the minimum clinically 
relevant improvement on the CARS-2 that can be used to 
determine patients responders to interventions for ASD. An 
improvement of 4.5 points on CARS-2 represents a mini-
mum clinically relevant change that can be used to classify 
the patient as responder.
As Authorities’ guidelines for assessing ASD in clini-
cal trial context recommends that endpoint on key efficacy 
measures should be supported by responder analyses using 
pre-specified criteria for response, the findings are of great 
use for further clinical trial targeting the core symptoms in 
ASD.
This initial finding represents an important new bench-
mark and may aid decision makers in evaluating the effi-
ciency of interventions in ASD.
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